Non Hodgkin Lymphoma Clinical Trial

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Summary

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT)
Participants with pathologically confirmed R/R NHL after failure or non-response to second line therapy, including but not limited to primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).
Participants must have measurable PET positive disease in both cHL and NHL cohorts.

Exclusion Criteria:

Aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic lymphoma, and NK/T-cell lymphoma/leukemia.
Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding.
Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies
Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents
Prior autologous stem cell transplantation (HDCT/ASCT)
History of allogeneic bone marrow transplantation.

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

68

Study ID:

NCT05255601

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 74 Locations for this study

See Locations Near You

Phoenix Childrens Hospital PCH - Phoenix Childrens Medical Group - Hematology Oncology
Phoenix Arizona, 85016, United States More Info
Michael Henry, Site 0024
Contact
602-933-2492
Lucile Packard Childrens Hospital - Stanford University
Palo Alto California, 94304, United States More Info
Lianna Marks, Site 0035
Contact
000-000-0000
Yale University
New Haven Connecticut, 06510, United States More Info
Stephanie Massaro, Site 0032
Contact
Local Institution - 0061
Wilmington Delaware, 19803, United States
Golisano Children's Hospital of Southwest Florida
Fort Myers Florida, 33908, United States More Info
Emad Salman, Site 0066
Contact
AdventHealth
Orlando Florida, 32804, United States More Info
Matthew Henderson, Site 0017
Contact
St. Mary's Medical Center
West Palm Beach Florida, 33407, United States
The Johns Hopkins Hospital JHH
Baltimore Maryland, 21287, United States More Info
Stacy Cooper, Site 0073
Contact
410-614-5055
University of Minnesota Medical School - Masonic Childrens Hospital
Minneapolis Minnesota, 55454, United States More Info
Peter Gordon, Site 0025
Contact
707-651-2577
University of Mississippi Medical Center
Jackson Mississippi, 39216, United States More Info
Betty Herrington, Site 0020
Contact
601-984-5220
Siteman Cancer Center - Washington University Medical Campus Location
Saint Louis Missouri, 63110, United States More Info
Robert Hayashi, Site 0012
Contact
314-454-6018
Hackensack University Medical Center HUMC - The Joseph M. Sanzari Childrens Hospital - Children's Cancer Institute
Hackensack New Jersey, 07601, United States More Info
Burton Appel, Site 0071
Contact
201-487-7340
Montefiore Medical Center
Bronx New York, 10467, United States More Info
Alice Lee, Site 0016
Contact
212-305-5808
Columbia University Medical Center
New York New York, 10032, United States More Info
Nobuko Hijiya, Site 0060
Contact
773-880-4562
New York Medical College
Valhalla New York, 10595, United States More Info
Mitchell Cairo, Site 0059
Contact
Penn State Health Milton S. Hershey Medical Center - Penn State Children's Hospital
Hershey Pennsylvania, 17033, United States More Info
Valerie Brown, Site 0019
Contact
215-805-5247
Vanderbilt-Ingram Cancer Center
Nashville Tennessee, 37232, United States More Info
Debra Friedman, Site 0014
Contact
615-936-1762
Dell Children's Medical Center of Central Texas (DCMC) - Strictly Pediatrics Subspecialty Center
Austin Texas, 78723, United States More Info
Shannon Cohn, Site 0029
Contact
512-628-1900
CHRISTUS Childrens
San Antonio Texas, 78207, United States More Info
Timothy Griffin, Site 0026
Contact
210-704-4275
UW Health - American Family Children's Hospital Pediatric Bone Marrow Transplant Clinic
Madison Wisconsin, 53792, United States
Local Institution - 0037
Randwick New South Wales, 2031, Australia More Info
Site 0037
Contact
Local Institution - 0039
South Brisbane Queensland, 4101, Australia More Info
Site 0039
Contact
Local Institution - 0042
Nedlands Western Australia, 6009, Australia More Info
Site 0042
Contact
Local Institution - 0063
Angers Angers Cedex 9, 49933, France More Info
Site 0063
Contact
Local Institution - 0048
Bordeaux , 33076, France More Info
Site 0048
Contact
Local Institution - 0033
Caen , 14033, France More Info
Site 0033
Contact
CHU Grenoble Alpes - Hopital Couple Enfant (HCE)
La Tronche , 38700, France More Info
Corinne Armari, Site 0067
Contact
Local Institution - 0021
Lyon , 69373, France More Info
Site 0021
Contact
Local Institution - 0034
Marseille , 13385, France
Local Institution - 0018
Montpellier , 34295, France More Info
Site 0018
Contact
Local Institution - 0006
Paris , 75571, France More Info
Site 0006
Contact
Assistance Publique-Hopitaux de Paris AP-HP - Hopital Universitaire Robert-Debre
Paris , 75935, France More Info
Thierry Leblanc, Site 0047
Contact
33140034740
Local Institution - 0022
Rennes , 35203, France
CHRU de Strasbourg-Hopital de Hautepierre
Strasbourg , 67000, France More Info
Catherine Paillard, Site 0052
Contact
Local Institution - 0056
Aachen , 52074, Germany
Local Institution - 0015
Berlin , 13353, Germany
Local Institution - 0028
Giessen , 35392, Germany
Local Institution - 0036
Hamburg , 20246, Germany
Local Institution - 0008
Muenster , 48149, Germany
Local Institution - 0051
Munich , 80337, Germany
Local Institution - 0041
Pavia PV, 27100, Italy More Info
Site 0041
Contact
Local Institution - 0010
Aviano , 33081, Italy More Info
Site 0010
Contact
Local Institution - 0007
Bologna , 40138, Italy More Info
Site 0007
Contact
Local Institution - 0040
Florence , 50139, Italy More Info
Site 0040
Contact
Local Institution - 0005
Genoa , 16147, Italy More Info
Site 0005
Contact
Local Institution - 0001
Milano , 20133, Italy More Info
Site 0001
Contact
Local Institution - 0070
Milan , 20162, Italy More Info
Site 0070
Contact
Local Institution - 0043
Monza , 20900, Italy More Info
Site 0043
Contact
Local Institution - 0013
Napoli , 80131, Italy More Info
Site 0013
Contact
Local Institution - 0065
Padova , 35128, Italy More Info
Site 0065
Contact
Osp. Pediatrico Bambino Gesu, IRCCS
Roma , 00165, Italy More Info
Franco Locatelli, Site 0002
Contact
390668593697
Local Institution - 0004
Turin , 10126, Italy More Info
Site 0004
Contact
Princess Maxima Center for pediatric oncology
Utrecht , 3584 , Netherlands More Info
Auke Beishuizen, Site 0057
Contact
31889727272
Local Institution - 0062
Pamplona Navarra, 31008, Spain More Info
Site 0062
Contact
Local Institution - 0046
Barcelona , 08035, Spain More Info
Site 0046
Contact
Local Institution - 0009
Barcelona , 8026, Spain More Info
Site 0009
Contact
Hospital Sant Juan de Deu Barcelona
Esplugues de Llobregat , 08950, Spain More Info
Veronica Celis, Site 0069
Contact
Local Institution - 0030
Madrid , 28009, Spain More Info
Site 0030
Contact
Local Institution - 0058
Madrid , 28027, Spain More Info
Site 0058
Contact
Local Institution - 0044
Madrid , 28040, Spain More Info
Site 0044
Contact
Local Institution - 0055
Madrid , 28041, Spain More Info
Site 0055
Contact
Local Institution - 0045
Madrid , 28046, Spain More Info
Site 0045
Contact
Local Institution - 0011
Santander , 39008, Spain More Info
Site 0011
Contact
Local Institution - 0038
Sevilla , 41009, Spain
Local Institution - 0023
Sevilla , 41013, Spain More Info
Site 0023
Contact
Local Institution - 0049
Valencia , 46026, Spain More Info
Site 0049
Contact
Local Institution - 0074
Liverpool England, L12 2, United Kingdom More Info
Site 0074
Contact
Local Institution - 0054
London Londonderry, NW1 2, United Kingdom More Info
Site 0054
Contact
Local Institution - 0003
Nottingham Nottinghamshire, NG5 1, United Kingdom More Info
Site 0003
Contact
Local Institution - 0050
Bristol Somerset, BS2 8, United Kingdom
Local Institution - 0053
Sutton Surrey, SM2 5, United Kingdom More Info
Site 0053
Contact
Local Institution - 0031
Birmingham West Midlands, B4 6N, United Kingdom
Local Institution - 0075
Cambridge , CB2 0, United Kingdom More Info
Site 0075
Contact
Local Institution - 0068
Newcastle upon Tyne , NE1 4, United Kingdom More Info
Site 0068
Contact

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

68

Study ID:

NCT05255601

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.